Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Expression of human inducible nitric oxide synthase in response to cytokines is regulated by hypoxia-inducible factor-1.

Lee M, Wang C, Jin SW, Labrecque MP, Beischlag TV, Brockman MA, Choy JC.

Free Radic Biol Med. 2018 Nov 1. pii: S0891-5849(18)32263-9. doi: 10.1016/j.freeradbiomed.2018.10.441. [Epub ahead of print]

PMID:
30391674
2.

Genotypic and Mechanistic Characterization of Subtype-specific HIV Adaptation to Host Cellular Immunity.

Kinloch NN, Lee GQ, Carlson JM, Jin SW, Brumme CJ, Byakwaga H, Muzoora C, Bwana MB, Cobarrubias KD, Hunt PW, Martin JN, Carrington M, Bangsberg DR, Harrigan PR, Brockman MA, Brumme ZL.

J Virol. 2018 Oct 10. pii: JVI.01502-18. doi: 10.1128/JVI.01502-18. [Epub ahead of print]

PMID:
30305354
3.

Phylogenetic approach to recover integration dates of latent HIV sequences within-host.

Jones BR, Kinloch NN, Horacsek J, Ganase B, Harris M, Harrigan PR, Jones RB, Brockman MA, Joy JB, Poon AFY, Brumme ZL.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8958-E8967. doi: 10.1073/pnas.1802028115. Epub 2018 Sep 5.

4.

HLA-C downregulation by HIV-1 adapts to host HLA genotype.

Bachtel ND, Umviligihozo G, Pickering S, Mota TM, Liang H, Del Prete GQ, Chatterjee P, Lee GQ, Thomas R, Brockman MA, Neil S, Carrington M, Bwana B, Bangsberg DR, Martin JN, Kallas EG, Donini CS, Cerqueira NB, O'Doherty UT, Hahn BH, Jones RB, Brumme ZL, Nixon DF, Apps R.

PLoS Pathog. 2018 Sep 4;14(9):e1007257. doi: 10.1371/journal.ppat.1007257. eCollection 2018 Sep.

5.

Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection.

Ojwach DBA, MacMillan D, Reddy T, Novitsky V, Brumme ZL, Brockman MA, Ndung'u T, Mann JK.

J Virol. 2018 Sep 12;92(19). pii: e00811-18. doi: 10.1128/JVI.00811-18. Print 2018 Oct 1.

PMID:
29997209
6.

Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products.

Richard K, Williams DE, de Silva ED, Brockman MA, Brumme ZL, Andersen RJ, Tietjen I.

Viruses. 2018 Jun 27;10(7). pii: E348. doi: 10.3390/v10070348.

7.

Novel HLA class I associations with HIV-1 control in a unique genetically admixed population.

Valenzuela-Ponce H, Alva-Hernández S, Garrido-Rodríguez D, Soto-Nava M, García-Téllez T, Escamilla-Gómez T, García-Morales C, Quiroz-Morales VS, Tapia-Trejo D, Del Arenal-Sánchez S, Prado-Galbarro FJ, Hernández-Juan R, Rodríguez-Aguirre E, Murakami-Ogasawara A, Mejía-Villatoro C, Escobar-Urias IY, Pinzón-Meza R, Pascale JM, Zaldivar Y, Porras-Cortés G, Quant-Durán C, Lorenzana I, Meza RI, Palou EY, Manzanero M, Cedillos RA, Aláez C, Brockman MA, Harrigan PR, Brumme CJ, Brumme ZL, Ávila-Ríos S, Reyes-Terán G; Mesoamerican HIV Project Group.

Sci Rep. 2018 Apr 17;8(1):6111. doi: 10.1038/s41598-018-23849-7.

8.

Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A.

Tietjen I, Williams DE, Read S, Kuang XT, Mwimanzi P, Wilhelm E, Markle T, Kinloch NN, Naphen CN, Tenney K, Mesplède T, Wainberg MA, Crews P, Bell B, Andersen RJ, Brumme ZL, Brockman MA.

Antiviral Res. 2018 Apr;152:94-103. doi: 10.1016/j.antiviral.2018.02.017. Epub 2018 Feb 22.

PMID:
29476895
9.

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia.

Tadesse BT, Kinloch NN, Baraki B, Lapointe HR, Cobarrubias KD, Brockman MA, Brumme CJ, Foster BA, Jerene D, Makonnen E, Aklillu E, Brumme ZL.

Viruses. 2018 Feb 1;10(2). pii: E60. doi: 10.3390/v10020060.

10.

Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico.

Soto-Nava M, Avila-Ríos S, Valenzuela-Ponce H, García-Morales C, Carlson JM, Tapia-Trejo D, Garrido-Rodriguez D, Alva-Hernández SN, García-Tellez TA, Murakami-Ogasawara A; International HIV Adaptation Collaborative, Mallal SA, John M, Brockman MA, Brumme CJ, Brumme ZL, Reyes-Teran G; HIV MexNet Group.

J Virol. 2018 Jan 2;92(2). pii: e01128-17. doi: 10.1128/JVI.01128-17. Print 2018 Jan 15.

11.

Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals.

Mwimanzi F, Toyoda M, Mahiti M, Mann JK, Martin JN, Bangsberg D, Brockman MA, Goulder P, Kirchhoff F, Brumme ZL, Ndung'u T, Ueno T.

J Virol. 2017 Dec 14;92(1). pii: e01409-17. doi: 10.1128/JVI.01409-17. Print 2018 Jan 1.

12.

The Croton megalobotrys Müll Arg. traditional medicine in HIV/AIDS management: Documentation of patient use, in vitro activation of latent HIV-1 provirus, and isolation of active phorbol esters.

Tietjen I, Ngwenya BN, Fotso G, Williams DE, Simonambango S, Ngadjui BT, Andersen RJ, Brockman MA, Brumme ZL, Andrae-Marobela K.

J Ethnopharmacol. 2018 Jan 30;211:267-277. doi: 10.1016/j.jep.2017.09.038. Epub 2017 Sep 29.

PMID:
28970153
13.

Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity.

Naidoo VL, Mann JK, Noble C, Adland E, Carlson JM, Thomas J, Brumme CJ, Thobakgale-Tshabalala CF, Brumme ZL, Brockman MA, Goulder PJR, Ndung'u T.

J Virol. 2017 Aug 10;91(17). pii: e00518-17. doi: 10.1128/JVI.00518-17. Print 2017 Sep 1.

14.

Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.

Kiguoya MW, Mann JK, Chopera D, Gounder K, Lee GQ, Hunt PW, Martin JN, Ball TB, Kimani J, Brumme ZL, Brockman MA, Ndung'u T.

J Virol. 2017 Jun 9;91(13). pii: e00253-17. doi: 10.1128/JVI.00253-17. Print 2017 Jul 1.

15.

In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach.

Rahimi A, Anmole G, Soto-Nava M, Escamilla-Gomez T, Markle T, Jin SW, Lee GQ, Harrigan PR, Bangsberg DR, Martin J, Avila-Rios S, Reyes-Teran G, Brockman MA, Brumme ZL.

J Virol Methods. 2017 Feb;240:32-41. doi: 10.1016/j.jviromet.2016.11.004. Epub 2016 Nov 16.

16.

Sesterterpenoids Isolated from the Sponge Phorbas sp. Activate Latent HIV-1 Provirus Expression.

Wang M, Tietjen I, Chen M, Williams DE, Daoust J, Brockman MA, Andersen RJ.

J Org Chem. 2016 Nov 18;81(22):11324-11334. Epub 2016 Nov 4.

PMID:
27768313
17.

Novel Acylguanidine-Based Inhibitor of HIV-1.

Mwimanzi P, Tietjen I, Miller SC, Shahid A, Cobarrubias K, Kinloch NN, Baraki B, Richard J, Finzi A, Fedida D, Brumme ZL, Brockman MA.

J Virol. 2016 Sep 29;90(20):9495-508. doi: 10.1128/JVI.01107-16. Print 2016 Oct 15.

18.

Croton megalobotrys Müll Arg. and Vitex doniana (Sweet): Traditional medicinal plants in a three-step treatment regimen that inhibit in vitro replication of HIV-1.

Tietjen I, Gatonye T, Ngwenya BN, Namushe A, Simonambanga S, Muzila M, Mwimanzi P, Xiao J, Fedida D, Brumme ZL, Brockman MA, Andrae-Marobela K.

J Ethnopharmacol. 2016 Sep 15;191:331-340. doi: 10.1016/j.jep.2016.06.040. Epub 2016 Jun 24.

PMID:
27350006
19.

Impact of pre-adapted HIV transmission.

Carlson JM, Du VY, Pfeifer N, Bansal A, Tan VY, Power K, Brumme CJ, Kreimer A, DeZiel CE, Fusi N, Schaefer M, Brockman MA, Gilmour J, Price MA, Kilembe W, Haubrich R, John M, Mallal S, Shapiro R, Frater J, Harrigan PR, Ndung'u T, Allen S, Heckerman D, Sidney J, Allen TM, Goulder PJ, Brumme ZL, Hunter E, Goepfert PA.

Nat Med. 2016 Jun;22(6):606-13. doi: 10.1038/nm.4100. Epub 2016 May 16.

20.

HIV-1 Vpu Mediates HLA-C Downregulation.

Apps R, Del Prete GQ, Chatterjee P, Lara A, Brumme ZL, Brockman MA, Neil S, Pickering S, Schneider DK, Piechocka-Trocha A, Walker BD, Thomas R, Shaw GM, Hahn BH, Keele BF, Lifson JD, Carrington M.

Cell Host Microbe. 2016 May 11;19(5):686-95. doi: 10.1016/j.chom.2016.04.005.

21.

Diagnostic Accuracy of the HemoCue Hb 301, STAT-Site MHgb and URIT-12 Point-of-Care Hemoglobin Meters in a Central Laboratory and a Community Based Clinic in Durban, South Africa.

Jaggernath M, Naicker R, Madurai S, Brockman MA, Ndung'u T, Gelderblom HC.

PLoS One. 2016 Apr 5;11(4):e0152184. doi: 10.1371/journal.pone.0152184. eCollection 2016.

22.

Relative Resistance of HLA-B to Downregulation by Naturally Occurring HIV-1 Nef Sequences.

Mahiti M, Toyoda M, Jia X, Kuang XT, Mwimanzi F, Mwimanzi P, Walker BD, Xiong Y, Brumme ZL, Brockman MA, Ueno T.

MBio. 2016 Jan 19;7(1):e01516-15. doi: 10.1128/mBio.01516-15.

23.

Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity.

Alsahafi N, Ding S, Richard J, Markle T, Brassard N, Walker B, Lewis GK, Kaufmann DE, Brockman MA, Finzi A.

J Virol. 2015 Dec 30;90(6):2993-3002. doi: 10.1128/JVI.02973-15.

24.

Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs.

Brockman MA, Jones RB, Brumme ZL.

Front Immunol. 2015 Oct 2;6:506. doi: 10.3389/fimmu.2015.00506. eCollection 2015. Review.

25.

Unciaphenol, an Oxygenated Analogue of the Bergman Cyclization Product of Uncialamycin Exhibits Anti-HIV Activity.

Williams DE, Bottriell H, Davies J, Tietjen I, Brockman MA, Andersen RJ.

Org Lett. 2015 Nov 6;17(21):5304-7. doi: 10.1021/acs.orglett.5b02664. Epub 2015 Oct 14.

PMID:
26465962
26.

Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function.

Shahid A, Olvera A, Anmole G, Kuang XT, Cotton LA, Plana M, Brander C, Brockman MA, Brumme ZL.

J Virol. 2015 Nov;89(22):11557-71. doi: 10.1128/JVI.01955-15. Epub 2015 Sep 9.

27.

A robust and scalable TCR-based reporter cell assay to measure HIV-1 Nef-mediated T cell immune evasion.

Anmole G, Kuang XT, Toyoda M, Martin E, Shahid A, Le AQ, Markle T, Baraki B, Jones RB, Ostrowski MA, Ueno T, Brumme ZL, Brockman MA.

J Immunol Methods. 2015 Nov;426:104-13. doi: 10.1016/j.jim.2015.08.010. Epub 2015 Aug 28.

PMID:
26319395
28.

Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors.

Toyoda M, Ogata Y, Mahiti M, Maeda Y, Kuang XT, Miura T, Jessen H, Walker BD, Brockman MA, Brumme ZL, Ueno T.

J Virol. 2015 Sep;89(18):9639-52. doi: 10.1128/JVI.01548-15. Epub 2015 Jul 15.

29.

Dynamic range of Nef-mediated evasion of HLA class II-restricted immune responses in early HIV-1 infection.

Mahiti M, Brumme ZL, Jessen H, Brockman MA, Ueno T.

Biochem Biophys Res Commun. 2015 Jul 31;463(3):248-54. doi: 10.1016/j.bbrc.2015.05.038. Epub 2015 May 19.

PMID:
25998395
30.

Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors.

Tietjen I, Ntie-Kang F, Mwimanzi P, Onguéné PA, Scull MA, Idowu TO, Ogundaini AO, Meva'a LM, Abegaz BM, Rice CM, Andrae-Marobela K, Brockman MA, Brumme ZL, Fedida D.

PLoS One. 2015 Apr 1;10(4):e0121099. doi: 10.1371/journal.pone.0121099. eCollection 2015.

31.

Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1.

Berger CT, Llano A, Carlson JM, Brumme ZL, Brockman MA, Cedeño S, Harrigan PR, Kaufmann DE, Heckerman D, Meyerhans A, Brander C.

J Virol. 2015 Apr;89(7):4015-9. doi: 10.1128/JVI.03435-14. Epub 2015 Jan 14.

32.

Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: association with disease progression and influence of immune pressure.

Mann JK, Chopera D, Omarjee S, Kuang XT, Le AQ, Anmole G, Danroth R, Mwimanzi P, Reddy T, Carlson J, Radebe M, Goulder PJR, Walker BD, Abdool Karim S, Novitsky V, Williamson C, Brockman MA, Brumme ZL, Ndung'u T.

Virology. 2014 Nov;468-470:214-225. doi: 10.1016/j.virol.2014.08.009. Epub 2014 Sep 3.

33.

Impaired Nef function is associated with early control of HIV-1 viremia.

Kuang XT, Li X, Anmole G, Mwimanzi P, Shahid A, Le AQ, Chong L, Qian H, Miura T, Markle T, Baraki B, Connick E, Daar ES, Jessen H, Kelleher AD, Little S, Markowitz M, Pereyra F, Rosenberg ES, Walker BD, Ueno T, Brumme ZL, Brockman MA.

J Virol. 2014 Sep 1;88(17):10200-13. doi: 10.1128/JVI.01334-14. Epub 2014 Jun 25.

34.

Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.

Cotton LA, Kuang XT, Le AQ, Carlson JM, Chan B, Chopera DR, Brumme CJ, Markle TJ, Martin E, Shahid A, Anmole G, Mwimanzi P, Nassab P, Penney KA, Rahman MA, Milloy MJ, Schechter MT, Markowitz M, Carrington M, Walker BD, Wagner T, Buchbinder S, Fuchs J, Koblin B, Mayer KH, Harrigan PR, Brockman MA, Poon AF, Brumme ZL.

PLoS Genet. 2014 Apr 24;10(4):e1004295. doi: 10.1371/journal.pgen.1004295. eCollection 2014 Apr.

35.

HIV-1 Nef and T-cell activation: a history of contradictions.

Markle TJ, Philip M, Brockman MA.

Future Virol. 2013 Apr 1;8(4). doi: 10.2217/fvl.13.20.

36.

Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes.

Mann JK, Byakwaga H, Kuang XT, Le AQ, Brumme CJ, Mwimanzi P, Omarjee S, Martin E, Lee GQ, Baraki B, Danroth R, McCloskey R, Muzoora C, Bangsberg DR, Hunt PW, Goulder PJ, Walker BD, Harrigan PR, Martin JN, Ndung'u T, Brockman MA, Brumme ZL.

Retrovirology. 2013 Sep 16;10:100. doi: 10.1186/1742-4690-10-100.

37.

No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.

Chopera DR, Mann JK, Mwimanzi P, Omarjee S, Kuang XT, Ndabambi N, Goodier S, Martin E, Naranbhai V, Karim SA, Karim QA, Brumme ZL, Ndung'u T, Williamson C, Brockman MA; CAPRISA 004 TRAPS Team.

PLoS One. 2013 Aug 28;8(8):e71758. doi: 10.1371/journal.pone.0071758. eCollection 2013.

38.

Dynamic range of Nef functions in chronic HIV-1 infection.

Mwimanzi P, Markle TJ, Ogata Y, Martin E, Tokunaga M, Mahiti M, Kuang XT, Walker BD, Brockman MA, Brumme ZL, Ueno T.

Virology. 2013 May 10;439(2):74-80. doi: 10.1016/j.virol.2013.02.005. Epub 2013 Mar 13.

39.

Attenuation of multiple Nef functions in HIV-1 elite controllers.

Mwimanzi P, Markle TJ, Martin E, Ogata Y, Kuang XT, Tokunaga M, Mahiti M, Pereyra F, Miura T, Walker BD, Brumme ZL, Brockman MA, Ueno T.

Retrovirology. 2013 Jan 7;10:1. doi: 10.1186/1742-4690-10-1.

41.
42.

Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in Japan.

Nomura S, Hosoya N, Brumme ZL, Brockman MA, Kikuchi T, Koga M, Nakamura H, Koibuchi T, Fujii T, Carlson JM, Heckerman D, Kawana-Tachikawa A, Iwamoto A, Miura T.

J Virol. 2013 Feb;87(3):1465-76. doi: 10.1128/JVI.02122-12. Epub 2012 Nov 14.

43.

HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates.

Jones RB, Garrison KE, Mujib S, Mihajlovic V, Aidarus N, Hunter DV, Martin E, John VM, Zhan W, Faruk NF, Gyenes G, Sheppard NC, Priumboom-Brees IM, Goodwin DA, Chen L, Rieger M, Muscat-King S, Loudon PT, Stanley C, Holditch SJ, Wong JC, Clayton K, Duan E, Song H, Xu Y, SenGupta D, Tandon R, Sacha JB, Brockman MA, Benko E, Kovacs C, Nixon DF, Ostrowski MA.

J Clin Invest. 2012 Dec;122(12):4473-89. doi: 10.1172/JCI64560. Epub 2012 Nov 12.

44.

Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1.

Carlson JM, Brumme CJ, Martin E, Listgarten J, Brockman MA, Le AQ, Chui CK, Cotton LA, Knapp DJ, Riddler SA, Haubrich R, Nelson G, Pfeifer N, Deziel CE, Heckerman D, Apps R, Carrington M, Mallal S, Harrigan PR, John M, Brumme ZL; International HIV Adaptation Collaborative.

J Virol. 2012 Dec;86(24):13202-16. doi: 10.1128/JVI.01998-12. Epub 2012 Oct 10.

45.

Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness.

Chopera DR, Cotton LA, Zawaira A, Mann JK, Ngandu NK, Ntale R, Carlson JM, Mlisana K, Woodman Z, de Assis Rosa D, Martin E, Miura T, Pereyra F, Walker BD, Gray CM, Martin DP, Ndung'u T, Brockman MA, Karim SA, Brumme ZL, Williamson C; CAPRISA 002 Study Team.

J Virol. 2012 Dec;86(24):13423-33. doi: 10.1128/JVI.02171-12. Epub 2012 Sep 26.

46.

Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure.

Brumme ZL, Chopera DR, Brockman MA.

Curr Opin Virol. 2012 Oct;2(5):599-605. doi: 10.1016/j.coviro.2012.08.003. Epub 2012 Aug 29. Review.

PMID:
22939190
47.

TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.

Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T, Brumme ZL, Schneidewind A, Piechocka-Trocha A, Cesa KT, Sela J, Cung TD, Toth I, Pereyra F, Yu XG, Douek DC, Kaufmann DE, Allen TM, Walker BD.

Nat Immunol. 2012 Jun 10;13(7):691-700. doi: 10.1038/ni.2342.

48.

Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.

Brockman MA, Chopera DR, Olvera A, Brumme CJ, Sela J, Markle TJ, Martin E, Carlson JM, Le AQ, McGovern R, Cheung PK, Kelleher AD, Jessen H, Markowitz M, Rosenberg E, Frahm N, Sanchez J, Mallal S, John M, Harrigan PR, Heckerman D, Brander C, Walker BD, Brumme ZL.

J Virol. 2012 Jun;86(12):6913-23. doi: 10.1128/JVI.07133-11. Epub 2012 Apr 11.

49.

Immune-mediated attenuation of HIV-1.

Chopera DR, Wright JK, Brockman MA, Brumme ZL.

Future Virol. 2011 Aug;6(8):917-928.

50.

Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity.

Wright JK, Naidoo VL, Brumme ZL, Prince JL, Claiborne DT, Goulder PJ, Brockman MA, Hunter E, Ndung'u T.

J Virol. 2012 Mar;86(6):3193-9. doi: 10.1128/JVI.06682-11. Epub 2012 Jan 11.

Supplemental Content

Loading ...
Support Center